REHOVOT, Israel, Feb. 10, 2020 /PRNewswire/ -- CollPlant
(NASDAQ: CLGN), a regenerative and
aesthetic medicine company, today announced the appointment of
Roger J. Pomerantz, M.D., F.A.C.P.
to its Board of Directors as Chairman, effective immediately. Dr.
Pomerantz is currently the President, Chief Executive Officer and
Chairman of the Board of Directors of ContraFect.
Based in the U.S., Dr. Pomerantz has extensive board experience
and currently serves on the boards of Intec Pharma and
VerImmune, in addition to ContraFect. He also serves as the
Chairman of the Scientific Advisory Board of Aridis
Pharmaceuticals. In addition, Dr. Pomerantz was a Venture
Partner at Flagship Pioneering from 2014 through 2019.
Previously, Dr. Pomerantz, served as the President, Chief
Executive Officer and Chairman of the Board of Seres Therapeutics,
where he continues to serve as advisor. Prior to joining Seres, Dr.
Pomerantz was Senior Vice President, Worldwide Head of Licensing
& Acquisition at Merck & Co., Inc and prior to that was
Senior Vice President and Global Franchise Head of Infectious
Diseases at Merck. Prior to joining Merck, Dr. Pomerantz was Global
Head of Infectious Diseases for Johnson & Johnson
Pharmaceuticals.
"Dr. Pomerantz's extensive knowledge of the life science
industry as a clinician, senior executive and board member is
exactly what we need as we bolster our strategic partnerships and
clinical development efforts for our recombinant human collagen
(rhCollagen) technology platform," said Yehiel Tal, CollPlant Chief Executive Officer.
"Roger is an excellent addition to our team and will play an
integral role in our mission to provide optimal treatment options
for patients through ground-breaking solutions in the field of
regenerative and aesthetic medicine."
Dr. Pomerantz received his B.A. in Biochemistry at the
Johns Hopkins University and his M.D.
at the Johns Hopkins School of
Medicine. He received post-graduate training at the
Massachusetts General Hospital,
Harvard Medical School and M.I.T. Dr.
Pomerantz is Board Certified in both Internal Medicine and
Infectious Diseases. He was Professor of Medicine, Biochemistry and
Molecular Pharmacology, Chief of Infectious Diseases, and the
Founding Director and Chair of the Institute for Human Virology and
Biodefense at the Thomas Jefferson
University and Medical School. He has developed twelve small
and large molecular drugs approved world-wide in important
diseases, including HIV, HCV,CMV, C. Diff, and tuberculosis.
"I'm thrilled to join CollPlant's Board at a pivotal time in the
Company's mission to revolutionize the fields of regenerative
and aesthetic medicine via its rhCollagen technology platform,"
said Dr. Pomerantz. "I believe that CollPlant's innovative
technology platform will help to meet the rapidly growing needs of
the medical aesthetics space by transforming soft tissue
regeneration as well as tissue and organ manufacturing. I am
looking forward to contributing the depth and breadth of my
experiences in pioneering novel solutions for patients around the
world."
About CollPlant
CollPlant is a regenerative and aesthetic medicine company
focused on 3D bioprinting of tissues and organs, and medical
aesthetics. Our products are based on our rhCollagen
(recombinant human collagen) that is produced with CollPlant's
proprietary plant based genetic engineering technology.
Our products address indications for the diverse fields of organ
and tissue repair, and are ushering in a new era in regenerative
medicine. Our flagship rhCollagen BioInk product line is ideal for
3D bioprinting of tissues and organs. CollPlant has a
licensing agreement with United Therapeutics, whereby United
Therapeutics is using CollPlant's BioInks in the manufacture of 3D
bioprinted lungs for transplant in humans. The Company has a
collaboration agreement with 3D Systems to advance and accelerate
tissue and scaffold bioprinting by delivering an integrated 3D
printer and BioInks solution to third parties. CollPlant's industry
collaboration partnerships include the Advanced Regenerative
Manufacturing Institute (ARMI) and RegenMed Development
Organization (ReMDO).
For more information about CollPlant, visit
http://www.collplant.com.
Safe Harbor Statements
This press release may include forward-looking statements.
Forward-looking statements may include, but are not limited to,
statements relating to CollPlant's objectives plans and strategies,
as well as statements, other than historical facts, that address
activities, events or developments that CollPlant intends, expects,
projects, believes or anticipates will or may occur in the future.
These statements are often characterized by terminology such as
"believes," "hopes," "may," "anticipates," "should," "intends,"
"plans," "will," "expects," "estimates," "projects," "positioned,"
"strategy" and similar expressions and are based on assumptions and
assessments made in light of management's experience and perception
of historical trends, current conditions, expected future
developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in
such statements. Many factors could cause CollPlant's actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements, including, but
not limited to, the following: the Company's history of significant
losses, its ability to continue as a going concern, and its need to
raise additional capital and its inability to obtain additional
capital on acceptable terms, or at all; the Company's expectations
regarding the timing and cost of commencing clinical trials with
respect to tissues and organs which are based on its rhCollagen
based BioInk, dermal fillers for aesthetics, VergenixSTR, and
VergenixFG; the Company's ability to obtain favorable pre-clinical
and clinical trial results; regulatory action with respect to
rhCollagen based BioInk, dermal fillers for aesthetics,
VergenixSTR, and VergenixFG including but not limited to acceptance
of an application for marketing authorization, review and approval
of such application, and, if approved, the scope of the approved
indication and labeling; commercial success and market acceptance
of the Company's rhCollagen based BioInk, dermal fillers for
aesthetics, VergenixSTR, and VergenixFG; the Company's ability to
establish sales and marketing capabilities or enter into agreements
with third parties and its reliance on third party distributors and
resellers; the Company's ability to establish and maintain
strategic partnerships and other corporate collaborations; the
Company's reliance on third parties to conduct some or all aspects
of its product manufacturing; the scope of protection the Company
is able to establish and maintain for intellectual property rights
and the Company's ability to operate its business without
infringing the intellectual property rights of others; the overall
global economic environment; the impact of competition and new
technologies; general market, political, and economic conditions in
the countries in which the Company operates; projected capital
expenditures and liquidity; changes in the Company's strategy; and
litigation and regulatory proceedings. More detailed information
about the risks and uncertainties affecting CollPlant is contained
under the heading "Risk Factors" included in CollPlant's most
recent annual report on Form 20-F filed with the SEC, and in other
filings that CollPlant has made and may make with the SEC in the
future. The forward-looking statements contained in this press
release are made as of the date of this press release and reflect
CollPlant's current views with respect to future events, and
CollPlant does not undertake and specifically disclaims any
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact at CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: +972-73-2325600
Email: Eran@collplant.com
Sophia Ononye, PhD MPH MBA
Founder & CEO, The Sophia Consulting Firm
Tel: +1-347-533-4578
E-mail: sophia@sophiaconsultingfirm.com
View original
content:http://www.prnewswire.com/news-releases/collplant-announces-appointment-of-roger-j-pomerantz-md-facp-as-chairman-of-the-board-of-directors-301001790.html
SOURCE CollPlant